ClinicalTrials.gg
CompletedNCT05997290Updated Apr 28, 2026Results posted

A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals

A Phase 2/3 interventional study of BNT162b2 (Omi XBB.1.5) and BNT162b2 (Omi JN.1) in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 37 sites in United States. Open to participants aged 12 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by BioNTech SE · Phase 2/3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,051
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.

Enrollment
12th of 54
1,051 · median 575
Started
2023
with 1 other
Phase 2/3
5 of 54
none open now
Registered
45th of 54
by date
Lead sponsor
20 of 54
BioNTech SE

Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 12th largest by enrollment, is one of 2 that started in 2023, is one of 5 in phase 2/3, and was the 45th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About BNT162 Vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 12 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing BNT162 Vaccine in COVID-19, or all of them as a file.
02

Study summary

The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people.

Substudy A:

  • This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose,

    • in people who are 12 years of age and older,
    • who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before the study vaccination (Visit 1).
  • The study is about 6 months long for each participant.
  • Participants will have at least 5 visits to the clinic.
  • At each clinic visit a blood sample will be taken.
  • At least 1 nasal swab will taken.

Substudy B:

  • This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose,

    • in people who are 12 years of age and older,
    • who are COVID-19 vaccine-naïve
    • who have had any positive SARS-CoV-2 test result >28 days before study vaccine administration.
  • The study is about 6 months long for each participant.
  • Participants will have at least 5 visits to the clinic.
  • At each clinic visit a blood sample will be taken.
  • At least 1 nasal swab will taken.

Substudy C:

  • This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi JN.1) and BNT162b2 (Omi KP.2) given as a single 30 µg dose to:

    • Cohort 1: people who are 18 years of age and older, who will receive BNT162b2 (Omi JN.1), and,
    • Cohort 2: people who are 12 years of age and older, who will receive BNT162b2 (Omi JN.1), and,
    • Cohort 3: people who are 18 years of age and older who will receive BNT162b2 (Omi KP.2).
    • Participants may have never received a COVID-19 vaccine or, may have previously received COVID-19 vaccine(s), with the most recent dose received at least 150 days before the study vaccination (Visit 1).
  • The study is about 6 months long for each participant.
  • Participants will have at least 6 visits (Cohorts 1 and 3) or at least 5 visits (Cohort 2) to the clinic.
  • At each clinic visit a blood sample will be taken.
  • At least 1 nasal swab will taken.
03

Conditions studied

  • SARS-CoV-2 Infection
  • COVID-19

Keywords

  • COVID-19
  • Coronavirus
  • Vaccine
  • SARS-CoV-2
  • RNA Vaccine
  • Vaccine-naïve
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

SSA

Inclusion Criteria:

  • Received at least 3 prior doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being a US-authorized Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before Visit 1 (Day 1).
  • 12 years of age and older
  • Healthy participants (stable pre-existing disease permitted).
  • Willing and able to comply with all scheduled visits/contacts, study procedures and lifestyle considerations.
  • Capable of giving, or parent(s)/legal guardian capable of giving, signed .

Exclusion Criteria

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study vaccines.
  • with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Any medical or psychiatric condition, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of myocarditis or pericarditis.
  • Receipt of systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic , eg, for cancer or an disease), or radiotherapy, within 60 days before enrollment or planned receipt through conclusion of the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, used for the treatment or prevention of COVID-19 or those that are considered immunosuppressive, from 60 days before study vaccination or planned receipt throughout the study.
  • Participation in other studies involving receipt of other study intervention within 28 days before enrollment. Anticipated participation in other studies involving other study intervention from enrollment through the end of this study.
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

SSB

Inclusion Criteria:

  • COVID-19 vaccine-naïve.
  • Any positive SARS-CoV-2 test result >28 days before study intervention administration.
  • 12 years of age and older.
  • Healthy participants (stable pre-existing disease permitted).
  • Willing and able to comply with all scheduled visits/contacts, study procedures and lifestyle considerations.
  • Capable of giving or parent(s)/legal guardian capable of giving, signed informed consent.

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study vaccines.
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Any medical or psychiatric condition, including recent (within the past year) or active suicidal ideation/behavior, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of myocarditis or pericarditis.
  • Receipt of systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids*, eg, for cancer or an autoimmune disease), or radiotherapy, within 60 days before enrollment or planned receipt through conclusion of the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies used for the treatment or prevention of COVID-19 or those that are considered immunosuppressive, from 60 days before study intervention administration or planned receipt throughout the study.
  • Participation in other studies involving receipt of other study intervention within 28 days before enrollment. Anticipated participation in other studies involving other study intervention from enrollment through the end of this study.
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.

SSC

Inclusion Criteria:

  • Cohort 1: 18 years of age and older
  • Cohort 2: 12 years of age and older
  • Cohort 3: 18 years of age and older
  • Healthy participants (stable pre-existing disease permitted).
  • Willing and able to comply with all scheduled visits/contacts, study procedures and lifestyle considerations.
  • Capable of giving, or parent(s)/legal guardian capable of giving, signed informed consent.

Exclusion Criteria

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the study vaccines.
  • Immunocompromised with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination.
  • Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
  • Women who are pregnant or breastfeeding.
  • Any medical or psychiatric condition, or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • History of myocarditis or pericarditis.
  • Receipt of systemic treatment with known immunosuppressant medications (including cytotoxic agents or systemic corticosteroids, eg, for cancer or an autoimmune disease), or radiotherapy, within 60 days before enrollment or planned receipt through conclusion of the study.
  • Receipt of blood/plasma products, immunoglobulin, or monoclonal antibodies, used for the treatment or prevention of COVID-19 or those that are considered immunosuppressive, from 60 days before study vaccination or planned receipt throughout the study.
  • Receipt of a COVID-19 vaccine less than 150 days before study intervention administration Visit 1 (Day 1).
  • Participation in other studies involving receipt of other study intervention within 28 days before enrollment. Anticipated participation in other studies involving other study intervention from enrollment through the end of this study.
  • Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,051 participants (actual)

Study arms

  • Experimental
    SSA: Group 1

    Participants 12 years of age and older, COVID-19 vaccine-experienced will receive 30 µg of BNT162b2 (Omi XBB.1.5) at Visit 1.

    Biological: BNT162b2 (Omi XBB.1.5)

  • Experimental
    SSB: Group 2

    Participants 12 years of age and older who were previously exposed to SARS-CoV-2 and are COVID-19 vaccine-naïve will receive 30 μg of BNT162b2 (Omi XBB.1.5) at Visit 1

    Biological: BNT162b2 (Omi XBB.1.5)

  • Experimental
    SSC: Group 3

    Cohort 1 - Participants 18 years of age and older will receive 30 µg of BNT162b2 (Omi JN.1) at Visit 1.

    Biological: BNT162b2 (Omi JN.1)

  • Experimental
    SSC: Group 4

    Cohort 2 - Participants 12 years of age and older will receive 30 µg of BNT162b2 (Omi JN.1) at Visit 1.

    Biological: BNT162b2 (Omi JN.1)

  • Experimental
    SSC - Group 5

    Cohort 3 - Participants 18 years of age and older who will receive 30 µg of BNT162b2 (Omi KP.2) at Visit 1.

    Biological: BNT162b2 (Omi KP.2)

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA

    Local reactions: pain at injection site, redness and swelling were recorded by participants in an electronic diary (e-diary) or as adverse events (AEs) in the case report form (CRF). Redness and swelling were recorded in measuring device units (mdu) (range: 1 to 21), 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.

    Time frame: Day 1 to Day 7 after vaccination

  2. Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSA

    Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature more than or equal to (\>=38) degree Celsius (C) and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous (IV) hydration. Diarrhea was graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.

    Time frame: Day 1 to Day 7 after vaccination

  3. Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination: SSA

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From vaccination on Day 1 up to 1 month after vaccination

  4. Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSA

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.

    Time frame: From vaccination on Day 1 up to 6 months after vaccination

  5. Geometric Mean Titers (GMT) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

    GMTs and 2-sided 95 percentage (%) confidence interval (CIs) were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ.

    Time frame: At 1 month after vaccination

  6. GMT of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: At 1 month after vaccination

  7. Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination: SSA and Historical Control of Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

    GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From before vaccination on Day 1 up to 1 month after vaccination

  8. GMFR of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

    GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: From before vaccination on Day 1 up to 1 month after vaccination

  9. Percentage of Participants With Seroresponse to SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.

    Time frame: At 1 month after vaccination

  10. Percentage of Participants With Seroresponse to SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

    Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.

    Time frame: At 1 month after vaccination

  11. Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSB

    Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.

    Time frame: Day 1 to Day 7 after vaccination

  12. Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSB

    Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.

    Time frame: Day 1 to Day 7 after vaccination

  13. Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSB

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From vaccination on Day 1 up to 1 month after vaccination

  14. Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSB

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.

    Time frame: From vaccination on Day 1 up to 6 months after vaccination

  15. Geometric Mean Ratio (GMR) of the SARS-CoV-2 XBB.1.5-Neutralizing Titers 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine-Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA

    GMTs / GMRs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) means / difference of LS means and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline assay results (log scale), age and vaccine group as covariates. Assay results below the LLOQ were set to 0.5\*LLOQ. GMT was reported in descriptive section and GMR was reported in statistical analysis section

    Time frame: At 1 month after vaccination

  16. Percentage of Participants and Difference in Percentage of Participants With Seroresponse to the XBB.1.5 Strain 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA

    Seroresponse was defined as achieving \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse. Percentage of participants with seroresponse were reported in descriptive section and difference in percentage of participants with seroresponse in SSB: All Age Groups (Vaccine Naive)- SSA: All Age Groups (Vaccine Experienced Control) were reported in statistical analysis section.

    Time frame: At 1 month after vaccination

  17. Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined

    Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.

    Time frame: Day 1 to Day 7 after vaccination

  18. Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined

    Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.

    Time frame: Day 1 to Day 7 after vaccination

  19. Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From vaccination on Day 1 up to 1 month after vaccination

  20. Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.

    Time frame: From vaccination on Day 1 up to 6 months after vaccination

  21. Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 3

    Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.

    Time frame: Day 1 to Day 7 after vaccination

  22. Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 3

    Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 deg C and categorized as \>= 38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and joint pain: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 events were classified by investigator or medically qualified person.

    Time frame: Day 1 to Day 7 after vaccination

  23. Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 3

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

    Time frame: From vaccination on Day 1 up to 1 month after vaccination

  24. Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 3

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.

    Time frame: From vaccination on Day 1 up to 6 months after vaccination

  25. GMTs of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: At 1 month after vaccination

  26. GMFR of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA

    GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.

    Time frame: From before Vaccination to 1 month after Vaccination

  27. Percentage of Participants With Seroresponse to SARS-CoV-2 OMI JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA

    Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.

    Time frame: At 1 month after vaccination

  28. GMTs of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and SSC Cohorts 1 + 2 Combined as Control

    GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: At 1 month after vaccination

  29. GMFR of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control

    GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.

    Time frame: From before vaccination on Day 1 up to 1 month after vaccination

  30. Percentage of Participants With Seroresponse to SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control

    Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.

    Time frame: At 1 month after vaccination

07

Results

Posted Apr 28, 2026

Participant flow

In this study there were 3 sub-studies: sub-study A (SSA), sub-study B (SSB), and sub-study C (SSC).

Participant flow — Overall Study
MilestoneSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 Years
Started3017721092534918951065151
Safety population3017420892534918921065151
Evaluable immunogenicity population2716718892434718911035050
Completed2917220392254418871004849
Not completed157028508632
Withdrew: Withdrawal by subject10206102110
Withdrew: Protocol violation00200000211
Withdrew: Lost to follow-up020022403201
Withdrew: Death00100000100
Withdrew: Assigned but not vaccinated03200003000
Withdrew: Other00000000010

Outcome measures

PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA

Local reactions: pain at injection site, redness and swelling were recorded by participants in an electronic diary (e-diary) or as adverse events (AEs) in the case report form (CRF). Redness and swelling were recorded in measuring device units (mdu) (range: 1 to 21), 1 mdu =0.5 centimeter (cm) and were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (emergency room \[ER\] visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSA
Percentage of participantsSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSA - All Age Groups
Redness: Any10.0 (2.1 to 26.5)4.0 (1.6 to 8.1)5.8 (3.0 to 10.0)5.4 (3.4 to 8.0)
Redness: Mild6.7 (0.8 to 22.1)3.4 (1.3 to 7.4)3.9 (1.7 to 7.5)3.9 (2.2 to 6.3)
Redness: Moderate3.3 (0.1 to 17.2)0.6 (0.0 to 3.2)1.9 (0.5 to 4.9)1.5 (0.5 to 3.2)
Redness: Severe0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Redness: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Swelling: Any16.7 (5.6 to 34.7)7.5 (4.0 to 12.4)5.8 (3.0 to 10.0)7.3 (5.0 to 10.3)
Swelling: Mild13.3 (3.8 to 30.7)5.7 (2.8 to 10.3)3.9 (1.7 to 7.5)5.4 (3.4 to 8.0)
Swelling: Moderate3.3 (0.1 to 17.2)1.7 (0.4 to 5.0)1.9 (0.5 to 4.9)2.0 (0.8 to 3.8)
Swelling: Severe0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Swelling: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Pain at the injection site: Any80.0 (61.4 to 92.3)75.9 (68.8 to 82.0)52.4 (45.4 to 59.4)64.4 (59.5 to 69.0)
Pain at the injection site: Mild50.0 (31.3 to 68.7)59.8 (52.1 to 67.1)46.6 (39.6 to 53.7)52.4 (47.5 to 57.4)
Pain at the injection site: Moderate30.0 (14.7 to 49.4)16.1 (11.0 to 22.4)5.8 (3.0 to 10.0)12.0 (9.0 to 15.5)
Pain at the injection site: Severe0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Pain at the injection site: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination: SSA

Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature more than or equal to (\>=38) degree Celsius (C) and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (did not interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24 hours (h), moderate: \>2 times in 24h, severe: required intravenous (IV) hydration. Diarrhea was graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSA
Percentage of participantsSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSA - All Age Groups
Fever: Any16.7 (5.6 to 34.7)4.0 (1.6 to 8.1)3.9 (1.7 to 7.5)4.9 (3.0 to 7.4)
Fever: >=38.0 degree C to 38.4 degree C10.0 (2.1 to 26.5)3.4 (1.3 to 7.4)2.4 (0.8 to 5.6)3.4 (1.9 to 5.7)
Fever: >38.4 degree C to 38.9 degree C3.3 (0.1 to 17.2)0.6 (0.0 to 3.2)1.0 (0.1 to 3.5)1.0 (0.3 to 2.5)
Fever: >38.9 degree C to 40.0 degree C3.3 (0.1 to 17.2)0 (0.0 to 2.1)0.5 (0.0 to 2.7)0.5 (0.1 to 1.8)
Fever: >40.0 degree C0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Fatigue: Any56.7 (37.4 to 74.5)56.9 (49.2 to 64.4)35.4 (28.9 to 42.4)46.1 (41.2 to 51.1)
Fatigue: Mild30.0 (14.7 to 49.4)31.6 (24.8 to 39.1)18.4 (13.4 to 24.4)24.9 (20.8 to 29.4)
Fatigue: Moderate26.7 (12.3 to 45.9)24.1 (18.0 to 31.2)17.0 (12.1 to 22.8)20.7 (16.9 to 25.0)
Fatigue: Severe0 (0.0 to 11.6)1.1 (0.1 to 4.1)0 (0.0 to 1.8)0.5 (0.1 to 1.8)
Fatigue: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Headache: Any36.7 (19.9 to 56.1)43.7 (36.2 to 51.4)26.2 (20.3 to 32.8)34.4 (29.8 to 39.2)
Headache: Mild30.0 (14.7 to 49.4)31.0 (24.3 to 38.5)20.4 (15.1 to 26.5)25.6 (21.5 to 30.1)
Headache: Moderate6.7 (0.8 to 22.1)12.6 (8.1 to 18.5)5.8 (3.0 to 10.0)8.8 (6.2 to 11.9)
Headache: Severe0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Headache: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Chills: Any20.0 (7.7 to 38.6)9.2 (5.3 to 14.5)9.2 (5.6 to 14.0)10.0 (7.3 to 13.3)
Chills: Mild10.0 (2.1 to 26.5)6.9 (3.6 to 11.7)6.3 (3.4 to 10.5)6.8 (4.6 to 9.7)
Chills: Moderate10.0 (2.1 to 26.5)2.3 (0.6 to 5.8)2.9 (1.1 to 6.2)3.2 (1.7 to 5.4)
Chills: Severe0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Chills: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Vomiting: Any0 (0.0 to 11.6)2.3 (0.6 to 5.8)0 (0.0 to 1.8)1.0 (0.3 to 2.5)
Vomiting: Mild0 (0.0 to 11.6)2.3 (0.6 to 5.8)0 (0.0 to 1.8)1.0 (0.3 to 2.5)
Vomiting: Moderate0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Vomiting: Severe0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Vomiting: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
Diarrhea: Any0 (0.0 to 11.6)13.2 (8.6 to 19.2)8.7 (5.3 to 13.5)10.0 (7.3 to 13.3)
Diarrhea: Mild0 (0.0 to 11.6)11.5 (7.2 to 17.2)7.3 (4.1 to 11.7)8.5 (6.0 to 11.7)
Diarrhea: Moderate0 (0.0 to 11.6)1.1 (0.1 to 4.1)1.5 (0.3 to 4.2)1.2 (0.4 to 2.8)
Diarrhea: Severe0 (0.0 to 11.6)0.6 (0.0 to 3.2)0 (0.0 to 1.8)0.2 (0.0 to 1.4)
Diarrhea: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
New or worsened muscle pain: Any23.3 (9.9 to 42.3)21.8 (15.9 to 28.7)12.1 (8.0 to 17.4)17.1 (13.6 to 21.1)
New or worsened muscle pain: Mild3.3 (0.1 to 17.2)12.1 (7.6 to 17.9)5.3 (2.7 to 9.4)8.0 (5.6 to 11.1)
New or worsened muscle pain: Moderate20.0 (7.7 to 38.6)9.8 (5.8 to 15.2)6.8 (3.8 to 11.1)9.0 (6.4 to 12.2)
New or worsened muscle pain: Severe0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
New or worsened muscle pain: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
New or worsened joint pain: Any16.7 (5.6 to 34.7)14.4 (9.5 to 20.5)7.8 (4.5 to 12.3)11.2 (8.3 to 14.7)
New or worsened joint pain: Mild6.7 (0.8 to 22.1)8.6 (4.9 to 13.8)5.3 (2.7 to 9.4)6.8 (4.6 to 9.7)
New or worsened joint pain: Moderate10.0 (2.1 to 26.5)5.7 (2.8 to 10.3)2.4 (0.8 to 5.6)4.4 (2.6 to 6.8)
New or worsened joint pain: Severe0 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
New or worsened joint pain: Grade 40 (0.0 to 11.6)0 (0.0 to 2.1)0 (0.0 to 1.8)0 (0.0 to 0.9)
PrimaryPercentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination: SSA

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A serious AE (SAE) was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From vaccination on Day 1 up to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination: SSA
Percentage of participantsSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSA - All Age Groups
Percentage of Participants With Adverse Events (AEs) From Vaccination Through 1 Month After Vaccination: SSA16.7 (5.6 to 34.7)7.5 (4.0 to 12.4)8.2 (4.8 to 12.8)8.5 (6.0 to 11.6)
PrimaryPercentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSA

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.

Time frame:
From vaccination on Day 1 up to 6 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSA
Percentage of participantsSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSA - All Age Groups
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSA3.3 (0.1 to 17.2)0 (0.0 to 2.1)1.9 (0.5 to 4.9)1.2 (0.4 to 2.8)
PrimaryGeometric Mean Titers (GMT) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

GMTs and 2-sided 95 percentage (%) confidence interval (CIs) were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ.

Time frame:
At 1 month after vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Titers (GMT) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
TiterSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsCohort 2/ 3 From C4591044 - Historical Control: 12-17 YearsCohort 2/ 3 From C4591044 - Historical Control: 18-55 YearsCohort 2/ 3 From C4591044 - Historical Control: >55 YearsSSA- All Age GroupsSSA - Historical Control: All Age Groups
Geometric Mean Titers (GMT) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C45910443632.1 (2043.8 to 6454.7)2503.6 (2003.0 to 3129.3)2606.8 (2065.5 to 3289.9)837.1 (459.5 to 1524.9)615.5 (459.0 to 825.2)560.4 (430.0 to 730.2)2622.3 (2246.6 to 3060.9)601.0 (499.5 to 723.1)
PrimaryGMT of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
At 1 month after vaccination
Reported as:
Geometric mean · Titer
GMT of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
TiterSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsCohort 2/ 3 From C4591044 - Historical Control: 12-17 YearsCohort 2/ 3 From C4591044 - Historical Control: 18-55 YearsCohort 2/ 3 From C4591044 - Historical Control: >55 YearsSSA- All Age GroupsSSA - Historical Control: All Age Groups
GMT of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C45910447903.6 (4961.5 to 12590.4)4831.8 (4044.5 to 5772.3)5046.1 (4123.3 to 6175.3)6376.3 (3568.4 to 11393.8)3868.2 (2974.8 to 5029.9)4122.7 (3261.2 to 5211.6)5105.1 (4483.4 to 5813.0)4146.0 (3512.6 to 4893.5)
PrimaryGeometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination: SSA and Historical Control of Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From before vaccination on Day 1 up to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination: SSA and Historical Control of Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
Fold riseSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsCohort 2/ 3 From C4591044 - Historical Control: 12-17 YearsCohort 2/ 3 From C4591044 - Historical Control: 18-55 YearsCohort 2/ 3 From C4591044 - Historical Control: >55 YearsSSA- All Age GroupsSSA - Historical Control: All Age Groups
Geometric Mean Fold Rise (GMFR) of SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers From Before Study Vaccination to 1 Month After Vaccination: SSA and Historical Control of Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C459104411.8 (6.3 to 22.2)10.7 (8.7 to 13.1)13.5 (10.7 to 17.1)7.1 (3.9 to 12.8)6.1 (4.5 to 8.3)5.2 (4.1 to 6.5)12.1 (10.4 to 14.0)5.7 (4.8 to 6.8)
PrimaryGMFR of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFR and 2-sided 95% CI were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
From before vaccination on Day 1 up to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
GMFR of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
Fold riseSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsCohort 2/ 3 From C4591044 - Historical Control: 12-17 YearsCohort 2/ 3 From C4591044 - Historical Control: 18-55 YearsCohort 2/ 3 From C4591044 - Historical Control: >55 YearsSSA- All Age GroupsSSA - Historical Control: All Age Groups
GMFR of SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C45910443.5 (2.2 to 5.8)4.3 (3.7 to 5.0)5.1 (4.3 to 6.2)5.7 (3.4 to 9.4)6.2 (4.6 to 8.4)7.4 (5.7 to 9.6)4.6 (4.1 to 5.2)6.8 (5.6 to 8.1)
PrimaryPercentage of Participants With Seroresponse to SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.

Time frame:
At 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
Percentage of participantsSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsCohort 2/ 3 From C4591044 - Historical Control: 12-17 YearsCohort 2/ 3 From C4591044 - Historical Control: 18-55 YearsCohort 2/ 3 From C4591044 - Historical Control: >55 YearsSSA- All Age GroupsSSA - Historical Control: All Age Groups
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi XBB.1.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C459104474.1 (53.7 to 88.9)76.4 (69.1 to 82.6)71.7 (64.6 to 78.1)66.7 (38.4 to 88.2)52.4 (41.1 to 63.6)51.0 (40.8 to 61.1)73.9 (69.2 to 78.3)52.8 (45.6 to 59.9)
PrimaryPercentage of Participants With Seroresponse to SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044

Seroresponse was defined as achieving \>= 4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse.

Time frame:
At 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C4591044
Percentage of participantsSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsCohort 2/ 3 From C4591044 - Historical Control: 12-17 YearsCohort 2/ 3 From C4591044 - Historical Control: 18-55 YearsCohort 2/ 3 From C4591044 - Historical Control: >55 YearsSSA- All Age GroupsSSA - Historical Control: All Age Groups
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi BA.4/BA.5-Neutralizing Titers at 1 Month After Vaccination: SSA and Historical Control of the Bivalent BNT162b2 (WT/Omi BA.4/BA.5) Group From Study C459104446.2 (26.6 to 66.6)43.7 (36.1 to 51.6)52.7 (45.3 to 60.0)73.3 (44.9 to 92.2)58.8 (47.6 to 69.4)65.0 (54.8 to 74.3)48.3 (43.2 to 53.4)63.0 (55.9 to 69.7)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination: SSB

Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSB
Percentage of participantsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSB - All Age Groups
Redness: Any0 (0.0 to 33.6)8.8 (5.6 to 13.0)2.0 (0.1 to 10.9)7.5 (4.8 to 11.0)
Redness: Mild0 (0.0 to 33.6)5.6 (3.1 to 9.2)2.0 (0.1 to 10.9)4.9 (2.8 to 7.9)
Redness: Moderate0 (0.0 to 33.6)2.8 (1.1 to 5.7)0 (0.0 to 7.3)2.3 (0.9 to 4.6)
Redness: Severe0 (0.0 to 33.6)0.4 (0.0 to 2.2)0 (0.0 to 7.3)0.3 (0.0 to 1.8)
Redness: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Swelling: Any11.1 (0.3 to 48.2)12.0 (8.2 to 16.7)10.2 (3.4 to 22.2)11.7 (8.3 to 15.8)
Swelling: Mild11.1 (0.3 to 48.2)6.8 (4.0 to 10.7)8.2 (2.3 to 19.6)7.1 (4.5 to 10.6)
Swelling: Moderate0 (0.0 to 33.6)5.2 (2.8 to 8.7)2.0 (0.1 to 10.9)4.5 (2.5 to 7.5)
Swelling: Severe0 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Swelling: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Pain at the injection site: Any44.4 (13.7 to 78.8)58.0 (51.6 to 64.2)36.7 (23.4 to 51.7)54.2 (48.5 to 59.9)
Pain at the injection site: Mild44.4 (13.7 to 78.8)36.4 (30.4 to 42.7)32.7 (19.9 to 47.5)36.0 (30.7 to 41.7)
Pain at the injection site: Moderate0 (0.0 to 33.6)21.2 (16.3 to 26.8)4.1 (0.5 to 14.0)17.9 (13.7 to 22.6)
Pain at the injection site: Severe0 (0.0 to 33.6)0.4 (0.0 to 2.2)0 (0.0 to 7.3)0.3 (0.0 to 1.8)
Pain at the injection site: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination: SSB

Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSB
Percentage of participantsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSB - All Age Groups
Fever: Any11.1 (0.3 to 48.2)2.4 (0.9 to 5.2)6.1 (1.3 to 16.9)3.2 (1.6 to 5.9)
Fever: >=38.0 degree C to 38.4 degree C0 (0.0 to 33.6)0.8 (0.1 to 2.9)4.1 (0.5 to 14.0)1.3 (0.4 to 3.3)
Fever: >38.4 degree C to 38.9 degree C11.1 (0.3 to 48.2)1.2 (0.2 to 3.5)0 (0.0 to 7.3)1.3 (0.4 to 3.3)
Fever: >38.9 degree C to 40.0 degree C0 (0.0 to 33.6)0.4 (0.0 to 2.2)2.0 (0.1 to 10.9)0.6 (0.1 to 2.3)
Fever: >40.0 degree C0 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Fatigue: Any11.1 (0.3 to 48.2)34.8 (28.9 to 41.1)24.5 (13.3 to 38.9)32.5 (27.3 to 38.0)
Fatigue: Mild0 (0.0 to 33.6)13.6 (9.6 to 18.5)8.2 (2.3 to 19.6)12.3 (8.9 to 16.5)
Fatigue: Moderate11.1 (0.3 to 48.2)21.2 (16.3 to 26.8)16.3 (7.3 to 29.7)20.1 (15.8 to 25.0)
Fatigue: Severe0 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Fatigue: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Headache: Any11.1 (0.3 to 48.2)30.8 (25.1 to 36.9)16.3 (7.3 to 29.7)27.9 (23.0 to 33.3)
Headache: Mild11.1 (0.3 to 48.2)12.0 (8.2 to 16.7)12.2 (4.6 to 24.8)12.0 (8.6 to 16.2)
Headache: Moderate0 (0.0 to 33.6)18.0 (13.4 to 23.3)4.1 (0.5 to 14.0)15.3 (11.4 to 19.8)
Headache: Severe0 (0.0 to 33.6)0.8 (0.1 to 2.9)0 (0.0 to 7.3)0.6 (0.1 to 2.3)
Headache: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Chills: Any11.1 (0.3 to 48.2)12.0 (8.2 to 16.7)10.2 (3.4 to 22.2)11.7 (8.3 to 15.8)
Chills: Mild11.1 (0.3 to 48.2)7.2 (4.3 to 11.1)4.1 (0.5 to 14.0)6.8 (4.3 to 10.2)
Chills: Moderate0 (0.0 to 33.6)4.8 (2.5 to 8.2)6.1 (1.3 to 16.9)4.9 (2.8 to 7.9)
Chills: Severe0 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Chills: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Vomiting: Any0 (0.0 to 33.6)4.8 (2.5 to 8.2)2.0 (0.1 to 10.9)4.2 (2.3 to 7.1)
Vomiting: Mild0 (0.0 to 33.6)2.4 (0.9 to 5.2)2.0 (0.1 to 10.9)2.3 (0.9 to 4.6)
Vomiting: Moderate0 (0.0 to 33.6)2.4 (0.9 to 5.2)0 (0.0 to 7.3)1.9 (0.7 to 4.2)
Vomiting: Severe0 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Vomiting: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
Diarrhea: Any11.1 (0.3 to 48.2)16.8 (12.4 to 22.0)8.2 (2.3 to 19.6)15.3 (11.4 to 19.8)
Diarrhea: Mild11.1 (0.3 to 48.2)10.0 (6.6 to 14.4)6.1 (1.3 to 16.9)9.4 (6.4 to 13.2)
Diarrhea: Moderate0 (0.0 to 33.6)6.4 (3.7 to 10.2)2.0 (0.1 to 10.9)5.5 (3.2 to 8.7)
Diarrhea: Severe0 (0.0 to 33.6)0.4 (0.0 to 2.2)0 (0.0 to 7.3)0.3 (0.0 to 1.8)
Diarrhea: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
New or worsened muscle pain: Any11.1 (0.3 to 48.2)18.0 (13.4 to 23.3)18.4 (8.8 to 32.0)17.9 (13.7 to 22.6)
New or worsened muscle pain: Mild11.1 (0.3 to 48.2)8.0 (5.0 to 12.1)10.2 (3.4 to 22.2)8.4 (5.6 to 12.1)
New or worsened muscle pain: Moderate0 (0.0 to 33.6)10.0 (6.6 to 14.4)8.2 (2.3 to 19.6)9.4 (6.4 to 13.2)
New or worsened muscle pain: Severe0 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
New or worsened muscle pain: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
New or worsened joint pain: Any11.1 (0.3 to 48.2)12.8 (8.9 to 17.6)12.2 (4.6 to 24.8)12.7 (9.2 to 16.9)
New or worsened joint pain: Mild11.1 (0.3 to 48.2)6.4 (3.7 to 10.2)6.1 (1.3 to 16.9)6.5 (4.0 to 9.9)
New or worsened joint pain: Moderate0 (0.0 to 33.6)6.4 (3.7 to 10.2)6.1 (1.3 to 16.9)6.2 (3.8 to 9.5)
New or worsened joint pain: Severe0 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
New or worsened joint pain: Grade 40 (0.0 to 33.6)0 (0.0 to 1.5)0 (0.0 to 7.3)0 (0.0 to 1.2)
PrimaryPercentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSB

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From vaccination on Day 1 up to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSB
Percentage of participantsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSB - All Age Groups
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSB0 (0.0 to 33.6)2.4 (0.9 to 5.1)2.0 (0.1 to 10.9)2.3 (0.9 to 4.6)
PrimaryPercentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSB

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.

Time frame:
From vaccination on Day 1 up to 6 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSB
Percentage of participantsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSB - All Age Groups
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSB0 (0.0 to 33.6)0.8 (0.1 to 2.8)2.0 (0.1 to 10.9)1.0 (0.2 to 2.8)
PrimaryGeometric Mean Ratio (GMR) of the SARS-CoV-2 XBB.1.5-Neutralizing Titers 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine-Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA

GMTs / GMRs and 2-sided 95% CIs were calculated by exponentiating the least square (LS) means / difference of LS means and the corresponding CIs based on analysis of log-transformed assay results using a linear regression model with baseline assay results (log scale), age and vaccine group as covariates. Assay results below the LLOQ were set to 0.5\*LLOQ. GMT was reported in descriptive section and GMR was reported in statistical analysis section

Time frame:
At 1 month after vaccination
Reported as:
Geometric mean · Titer
Geometric Mean Ratio (GMR) of the SARS-CoV-2 XBB.1.5-Neutralizing Titers 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine-Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA
TiterSSB: All Age Groups (Vaccine Naive)SSA: All Age Groups (Vaccine Experienced Control)
Geometric Mean Ratio (GMR) of the SARS-CoV-2 XBB.1.5-Neutralizing Titers 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine-Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA4951.6 (4222.8 to 5806.2)2566.5 (2186.8 to 3012.1)
Statistical analysis
  • SSB: All Age Groups (Vaccine Naive) vs SSA: All Age Groups (Vaccine Experienced Control) · Gmr: 1.93 · 95% CI 1.52 to 2.44
PrimaryPercentage of Participants and Difference in Percentage of Participants With Seroresponse to the XBB.1.5 Strain 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA

Seroresponse was defined as achieving \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, the postvaccination assay result of \>= 4\* LLOQ was considered a seroresponse. Percentage of participants with seroresponse were reported in descriptive section and difference in percentage of participants with seroresponse in SSB: All Age Groups (Vaccine Naive)- SSA: All Age Groups (Vaccine Experienced Control) were reported in statistical analysis section.

Time frame:
At 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants and Difference in Percentage of Participants With Seroresponse to the XBB.1.5 Strain 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA
Percentage of participantsSSB: All Age Groups (Vaccine Naive)SSA: All Age Groups (Vaccine Experienced Control)
Percentage of Participants and Difference in Percentage of Participants With Seroresponse to the XBB.1.5 Strain 1 Month After BNT162b2 (Omi XBB.1.5) COVID-19 Vaccine Naive Participants in SSB Versus Vaccine-Experienced Participants in SSA84.9 (80.3 to 88.8)73.9 (68.5 to 78.8)
Statistical analysis
  • SSB: All Age Groups (Vaccine Naive) vs SSA: All Age Groups (Vaccine Experienced Control) · Difference in percentage of participants: 7.31 · 95% CI 1.34 to 13.282-Sided CI, based on the Miettinen and Nurminen method stratified by baseline neutralizing titer category (\< median, \>= median) and age group (\< median, \>= median).
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined

Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
Percentage of participantsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age Groups
Redness: any11.1 (1.4 to 34.7)8.7 (3.8 to 16.4)9.4 (4.6 to 16.7)9.3 (5.7 to 13.9)
Redness: mild5.6 (0.1 to 27.3)1.1 (0.0 to 5.9)6.6 (2.7 to 13.1)4.2 (1.9 to 7.8)
Redness: moderate5.6 (0.1 to 27.3)6.5 (2.4 to 13.7)2.8 (0.6 to 8.0)4.6 (2.2 to 8.3)
Redness: severe0 (0.0 to 18.5)1.1 (0.0 to 5.9)0 (0.0 to 3.4)0.5 (0.0 to 2.6)
Redness: grade 40 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
Swelling: any0 (0.0 to 18.5)13.0 (6.9 to 21.7)11.3 (6.0 to 18.9)11.1 (7.3 to 16.1)
Swelling: mild0 (0.0 to 18.5)8.7 (3.8 to 16.4)4.7 (1.5 to 10.7)6.0 (3.2 to 10.1)
Swelling: moderate0 (0.0 to 18.5)4.3 (1.2 to 10.8)6.6 (2.7 to 13.1)5.1 (2.6 to 8.9)
Swelling: severe0 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
Swelling: grade 40 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
Pain at the injection site: any88.9 (65.3 to 98.6)72.8 (62.6 to 81.6)49.1 (39.2 to 59.0)62.5 (55.7 to 69.0)
Pain at the injection site: mild55.6 (30.8 to 78.5)58.7 (47.9 to 68.9)42.5 (32.9 to 52.4)50.5 (43.6 to 57.3)
Pain at the injection site: moderate27.8 (9.7 to 53.5)12.0 (6.1 to 20.4)5.7 (2.1 to 11.9)10.2 (6.5 to 15.0)
Pain at the injection site: severe5.6 (0.1 to 27.3)2.2 (0.3 to 7.6)0.9 (0.0 to 5.1)1.9 (0.5 to 4.7)
Pain at the injection site: grade 40 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined

Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 degree C and categorized as \>= 38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, chills, new or worsened muscle pain and joint pain were graded as: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea were graded as: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 systemic events were classified by investigator or medically qualified person.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
Percentage of participantsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age Groups
Fever: any11.1 (1.4 to 34.7)4.3 (1.2 to 10.8)1.9 (0.2 to 6.8)3.7 (1.6 to 7.2)
Fever: >=38.0 degree C to 38.4 degree C5.6 (0.1 to 27.3)2.2 (0.3 to 7.6)1.0 (0.0 to 5.2)1.9 (0.5 to 4.7)
Fever: >38.4 degree C to 38.9 degree C5.6 (0.1 to 27.3)2.2 (0.3 to 7.6)0 (0.0 to 3.5)1.4 (0.3 to 4.0)
Fever: >38.9 degree C to 40.0 degree C0 (0.0 to 18.5)0 (0.0 to 3.9)1.0 (0.0 to 5.2)0.5 (0.0 to 2.6)
Fever: >40.0 degree C0 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.5)0 (0.0 to 1.7)
Fatigue: any55.6 (30.8 to 78.5)47.8 (37.3 to 58.5)29.2 (20.8 to 38.9)39.4 (32.8 to 46.2)
Fatigue: mild11.1 (1.4 to 34.7)22.8 (14.7 to 32.8)17.0 (10.4 to 25.5)19.0 (14.0 to 24.9)
Fatigue: moderate38.9 (17.3 to 64.3)25.0 (16.6 to 35.1)11.3 (6.0 to 18.9)19.4 (14.4 to 25.4)
Fatigue: severe0 (0.0 to 18.5)0 (0.0 to 3.9)0.9 (0.0 to 5.1)0.5 (0.0 to 2.6)
Fatigue: grade 45.6 (0.1 to 27.3)0 (0.0 to 3.9)0 (0.0 to 3.4)0.5 (0.0 to 2.6)
Headache: any61.1 (35.7 to 82.7)35.9 (26.1 to 46.5)17.9 (11.2 to 26.6)29.2 (23.2 to 35.7)
Headache: mild44.4 (21.5 to 69.2)21.7 (13.8 to 31.6)13.2 (7.4 to 21.2)19.4 (14.4 to 25.4)
Headache: moderate11.1 (1.4 to 34.7)13.0 (6.9 to 21.7)3.8 (1.0 to 9.4)8.3 (5.0 to 12.9)
Headache: severe0 (0.0 to 18.5)1.1 (0.0 to 5.9)0.9 (0.0 to 5.1)0.9 (0.1 to 3.3)
Headache: grade 45.6 (0.1 to 27.3)0 (0.0 to 3.9)0 (0.0 to 3.4)0.5 (0.0 to 2.6)
Chills: any44.4 (21.5 to 69.2)17.4 (10.3 to 26.7)8.5 (4.0 to 15.5)15.3 (10.8 to 20.8)
Chills: mild27.8 (9.7 to 53.5)10.9 (5.3 to 19.1)4.7 (1.5 to 10.7)9.3 (5.7 to 13.9)
Chills: moderate11.1 (1.4 to 34.7)6.5 (2.4 to 13.7)2.8 (0.6 to 8.0)5.1 (2.6 to 8.9)
Chills: severe0 (0.0 to 18.5)0 (0.0 to 3.9)0.9 (0.0 to 5.1)0.5 (0.0 to 2.6)
Chills: grade 45.6 (0.1 to 27.3)0 (0.0 to 3.9)0 (0.0 to 3.4)0.5 (0.0 to 2.6)
Vomiting: any11.1 (1.4 to 34.7)2.2 (0.3 to 7.6)0.9 (0.0 to 5.1)2.3 (0.8 to 5.3)
Vomiting: mild5.6 (0.1 to 27.3)2.2 (0.3 to 7.6)0 (0.0 to 3.4)1.4 (0.3 to 4.0)
Vomiting: moderate0 (0.0 to 18.5)0 (0.0 to 3.9)0.9 (0.0 to 5.1)0.5 (0.0 to 2.6)
Vomiting: severe5.6 (0.1 to 27.3)0 (0.0 to 3.9)0 (0.0 to 3.4)0.5 (0.0 to 2.6)
Vomiting: grade 40 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
Diarrhoea: any0 (0.0 to 18.5)9.8 (4.6 to 17.8)7.5 (3.3 to 14.3)7.9 (4.7 to 12.3)
Diarrhoea: mild0 (0.0 to 18.5)6.5 (2.4 to 13.7)6.6 (2.7 to 13.1)6.0 (3.2 to 10.1)
Diarrhoea: moderate0 (0.0 to 18.5)3.3 (0.7 to 9.2)0.9 (0.0 to 5.1)1.9 (0.5 to 4.7)
Diarrhoea: severe0 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
Diarrhoea: grade 40 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
New or worsened muscle pain: any33.3 (13.3 to 59.0)17.4 (10.3 to 26.7)10.4 (5.3 to 17.8)15.3 (10.8 to 20.8)
New or worsened muscle pain: mild16.7 (3.6 to 41.4)8.7 (3.8 to 16.4)5.7 (2.1 to 11.9)7.9 (4.7 to 12.3)
New or worsened muscle pain: moderate11.1 (1.4 to 34.7)8.7 (3.8 to 16.4)4.7 (1.5 to 10.7)6.9 (3.9 to 11.2)
New or worsened muscle pain: severe5.6 (0.1 to 27.3)0 (0.0 to 3.9)0 (0.0 to 3.4)0.5 (0.0 to 2.6)
New or worsened muscle pain: grade 40 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
New or worsened joint pain: any11.1 (1.4 to 34.7)8.7 (3.8 to 16.4)7.5 (3.3 to 14.3)8.3 (5.0 to 12.9)
New or worsened joint pain: mild5.6 (0.1 to 27.3)6.5 (2.4 to 13.7)3.8 (1.0 to 9.4)5.1 (2.6 to 8.9)
New or worsened joint pain: moderate0 (0.0 to 18.5)2.2 (0.3 to 7.6)3.8 (1.0 to 9.4)2.8 (1.0 to 5.9)
New or worsened joint pain: severe5.6 (0.1 to 27.3)0 (0.0 to 3.9)0 (0.0 to 3.4)0.5 (0.0 to 2.6)
New or worsened joint pain: grade 40 (0.0 to 18.5)0 (0.0 to 3.9)0 (0.0 to 3.4)0 (0.0 to 1.7)
PrimaryPercentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From vaccination on Day 1 up to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
Percentage of participantsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age Groups
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined5.6 (0.1 to 27.3)3.3 (0.7 to 9.2)8.5 (4.0 to 15.5)6.0 (3.2 to 10.1)
PrimaryPercentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.

Time frame:
From vaccination on Day 1 up to 6 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined
Percentage of participantsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age Groups
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 2; SSC Cohort 1 and 2 Combined0 (0.0 to 18.5)1.1 (0.0 to 5.9)2.8 (0.6 to 8.0)1.9 (0.5 to 4.7)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 3

Local reactions: pain at injection site, redness and swelling were recorded by participants in an e-diary or as AEs in the CRF. Redness and swelling were recorded in mdu (range:1 to 21), 1 mdu= 0.5 cm and were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm), severe (\>10.0 cm) and Grade 4 (necrosis \[swelling\] and necrosis or exfoliative dermatitis \[redness\]). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), severe (prevented daily activity) and Grade 4 (ER visit or hospitalization for severe pain at injection site). Grade 4 local reactions were classified by investigator or medically qualified person.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Vaccination: SSC Cohort 3
Percentage of participantsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsSSC- Cohort 3 Combined: All Age Groups
Redness: any5.9 (1.2 to 16.2)2.0 (0.0 to 10.4)3.9 (1.1 to 9.7)
Redness: mild2.0 (0.0 to 10.4)2.0 (0.0 to 10.4)2.0 (0.2 to 6.9)
Redness: moderate3.9 (0.5 to 13.5)0 (0.0 to 7.0)2.0 (0.2 to 6.9)
Redness: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Redness: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Swelling: any9.8 (3.3 to 21.4)3.9 (0.5 to 13.5)6.9 (2.8 to 13.6)
Swelling: mild3.9 (0.5 to 13.5)3.9 (0.5 to 13.5)3.9 (1.1 to 9.7)
Swelling: moderate5.9 (1.2 to 16.2)0 (0.0 to 7.0)2.9 (0.6 to 8.4)
Swelling: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Swelling: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Pain at the injection site: any72.5 (58.3 to 84.1)45.1 (31.1 to 59.7)58.8 (48.6 to 68.5)
Pain at the injection site: mild60.8 (46.1 to 74.2)39.2 (25.8 to 53.9)50.0 (39.9 to 60.1)
Pain at the injection site: moderate11.8 (4.4 to 23.9)5.9 (1.2 to 16.2)8.8 (4.1 to 16.1)
Pain at the injection site: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Pain at the injection site: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 3

Systemic events were recorded by participants in an e-diary or as AEs in the CRF. Fever: defined as oral temperature \>=38 deg C and categorized as \>= 38.0-38.4 deg C, \>38.4-38.9 deg C, \>38.9-40.0 deg C and \>40.0 deg C. Fatigue, headache, chills, new or worsened muscle pain and joint pain: mild (didn't interfere with activity), moderate (some interference with activity), severe (prevented daily routine activity). Vomiting: mild: 1-2 times in 24h, moderate: \>2 times in 24h, severe: required IV hydration. Diarrhea: mild: 2-3 loose stools in 24h, moderate: 4-5 loose stools in 24h, severe: 6 or more loose stools in 24h. Grade 4 for all events except fever: ER visit/hospitalization. Grade 4 events were classified by investigator or medically qualified person.

Time frame:
Day 1 to Day 7 after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Vaccination: SSC Cohort 3
Percentage of participantsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsSSC- Cohort 3 Combined: All Age Groups
Fever: any3.9 (0.5 to 13.5)3.9 (0.5 to 13.5)3.9 (1.1 to 9.7)
Fever: >=38.0 degree C to 38.4 degree C3.9 (0.5 to 13.5)2.0 (0.0 to 10.4)2.9 (0.6 to 8.4)
Fever: >38.4 degree C to 38.9 degree C0 (0.0 to 7.0)2.0 (0.0 to 10.4)1.0 (0.0 to 5.3)
Fever: >38.9 degree C to 40.0 degree C0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Fever: >40.0 degree C0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Fatigue: any58.8 (44.2 to 72.4)33.3 (20.8 to 47.9)46.1 (36.2 to 56.2)
Fatigue: mild33.3 (20.8 to 47.9)19.6 (9.8 to 33.1)26.5 (18.2 to 36.1)
Fatigue: moderate25.5 (14.3 to 39.6)13.7 (5.7 to 26.3)19.6 (12.4 to 28.6)
Fatigue: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Fatigue: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Headache: any39.2 (25.8 to 53.9)17.6 (8.4 to 30.9)28.4 (19.9 to 38.2)
Headache: mild27.5 (15.9 to 41.7)11.8 (4.4 to 23.9)19.6 (12.4 to 28.6)
Headache: moderate11.8 (4.4 to 23.9)5.9 (1.2 to 16.2)8.8 (4.1 to 16.1)
Headache: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Headache: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Chills: any7.8 (2.2 to 18.9)9.8 (3.3 to 21.4)8.8 (4.1 to 16.1)
Chills: mild3.9 (0.5 to 13.5)9.8 (3.3 to 21.4)6.9 (2.8 to 13.6)
Chills: moderate3.9 (0.5 to 13.5)0 (0.0 to 7.0)2.0 (0.2 to 6.9)
Chills: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Chills: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Vomiting: any2.0 (0.0 to 10.4)3.9 (0.5 to 13.5)2.9 (0.6 to 8.4)
Vomiting: mild2.0 (0.0 to 10.4)2.0 (0.0 to 10.4)2.0 (0.2 to 6.9)
Vomiting: moderate0 (0.0 to 7.0)2.0 (0.0 to 10.4)1.0 (0.0 to 5.3)
Vomiting: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Vomiting: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Diarrhea: any11.8 (4.4 to 23.9)7.8 (2.2 to 18.9)9.8 (4.8 to 17.3)
Diarrhea: mild7.8 (2.2 to 18.9)7.8 (2.2 to 18.9)7.8 (3.4 to 14.9)
Diarrhea: moderate3.9 (0.5 to 13.5)0 (0.0 to 7.0)2.0 (0.2 to 6.9)
Diarrhea: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
Diarrhea: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
New or worsened muscle pain: any33.3 (20.8 to 47.9)9.8 (3.3 to 21.4)21.6 (14.0 to 30.8)
New or worsened muscle pain: mild17.6 (8.4 to 30.9)7.8 (2.2 to 18.9)12.7 (7.0 to 20.8)
New or worsened muscle pain: moderate15.7 (7.0 to 28.6)2.0 (0.0 to 10.4)8.8 (4.1 to 16.1)
New or worsened muscle pain: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
New or worsened muscle pain: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
New or worsened joint pain: any13.7 (5.7 to 26.3)3.9 (0.5 to 13.5)8.8 (4.1 to 16.1)
New or worsened joint pain: mild11.8 (4.4 to 23.9)2.0 (0.0 to 10.4)6.9 (2.8 to 13.6)
New or worsened joint pain: moderate2.0 (0.0 to 10.4)2.0 (0.0 to 10.4)2.0 (0.2 to 6.9)
New or worsened joint pain: severe0 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
New or worsened joint pain: grade 40 (0.0 to 7.0)0 (0.0 to 7.0)0 (0.0 to 3.6)
PrimaryPercentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 3

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with use of study intervention, whether or not considered related to study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event. AEs included both SAEs and all non-SAEs. Only AEs collected by non-systematic assessment (i.e., excluding local reactions and systemic events) were reported in this outcome measure.

Time frame:
From vaccination on Day 1 up to 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 3
Percentage of participantsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsSSC- Cohort 3 Combined: All Age Groups
Percentage of Participants With AEs From Vaccination Through 1 Month After Vaccination: SSC Cohort 313.7 (5.7 to 26.3)5.9 (1.2 to 16.2)9.8 (4.8 to 17.3)
PrimaryPercentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 3

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A SAE was defined as any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect, any other event pre-specified in protocol of the study; or considered as an important medical event.

Time frame:
From vaccination on Day 1 up to 6 months after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 3
Percentage of participantsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsSSC- Cohort 3 Combined: All Age Groups
Percentage of Participants With SAEs From Vaccination Through 6 Months After the Study Vaccination: SSC Cohort 30 (0.0 to 7.0)2.0 (0.0 to 10.4)1.0 (0.0 to 5.3)
PrimaryGMTs of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
At 1 month after vaccination
Reported as:
Geometric mean · Titers
GMTs of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
TitersSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age GroupsSSA - Historical Control: 12-17 YearsSSA - Historical Control: 18-55 YearsSSA - Historical Control: >55 YearsSSA - Historical Control: All Age Groups
Omicron JN.13920.4 (2296.3 to 6693.2)1895.8 (1456.8 to 2467.0)2275.2 (1771.0 to 2923.1)2203.3 (1855.7 to 2616.0)1979.1 (928.5 to 4218.1)1060.1 (841.8 to 1335.1)1090.4 (829.7 to 1433.1)1133.8 (950.7 to 1352.2)
Omicron XBB.1.55893.1 (3472.2 to 10002.0)1926.7 (1361.8 to 2725.9)2415.2 (1815.5 to 3213.1)2364.4 (1917.4 to 2915.6)5744.9 (3040.8 to 10853.8)2566.8 (1963.2 to 3355.9)2759.8 (2028.9 to 3753.9)2848.1 (2341.9 to 3463.8)
PrimaryGMFR of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA

GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.

Time frame:
From before Vaccination to 1 month after Vaccination
Reported as:
Geometric mean · Fold rise
GMFR of SARS-CoV-2 Omi JN.1 and XBB.1.5 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
Fold riseSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age GroupsSSA - Historical Control: 12-17 YearsSSA - Historical Control: 18-55 YearsSSA - Historical Control: >55 YearsSSA - Historical Control: All Age Groups
Omicron JN.115.5 (5.8 to 41.5)11.2 (8.3 to 15.0)11.4 (8.4 to 15.4)11.6 (9.4 to 14.2)3.9 (2.5 to 6.1)5.8 (4.5 to 7.6)9.6 (7.2 to 12.9)7.2 (6.0 to 8.7)
Omicron XBB.1.515.9 (6.3 to 40.1)7.0 (5.0 to 9.8)8.3 (6.0 to 11.4)8.1 (6.5 to 10.2)10.2 (6.2 to 16.8)12.3 (9.4 to 16.1)14.2 (11.0 to 18.4)13.0 (10.9 to 15.5)
PrimaryPercentage of Participants With Seroresponse to SARS-CoV-2 OMI JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA

Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.

Time frame:
At 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to SARS-CoV-2 OMI JN.1 and XBB.1.5 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohorts 1 + 2 Combined and Historical Control Group From SSA
Percentage of participantsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age GroupsSSA - Historical Control: 12-17 YearsSSA - Historical Control: 18-55 YearsSSA - Historical Control: >55 YearsSSA - Historical Control: All Age Groups
Omicron JN.170.6 (44.0 to 89.7)73.6 (63.3 to 82.3)68.0 (58.0 to 76.8)70.6 (64.0 to 76.7)47.1 (23.0 to 72.2)63.9 (52.6 to 74.1)70.1 (60.0 to 79.0)65.5 (58.4 to 72.1)
Omicron XBB.1.566.7 (41.0 to 86.7)58.2 (47.4 to 68.5)61.2 (51.1 to 70.6)60.4 (53.5 to 67.0)82.4 (56.6 to 96.2)82.4 (72.6 to 89.8)81.6 (72.5 to 88.7)82.0 (76.0 to 87.1)
PrimaryGMTs of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and SSC Cohorts 1 + 2 Combined as Control

GMTs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
At 1 month after vaccination
Reported as:
Geometric mean · Titer
GMTs of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and SSC Cohorts 1 + 2 Combined as Control
TiterSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsSSC- Cohort 3 Combined: All Age GroupsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age Groups
Omicron KP.22037.8 (1326.3 to 3130.9)2498.8 (1590.4 to 3926.0)2256.5 (1660.2 to 3067.0)890.4 (648.6 to 1222.2)858.5 (641.5 to 1148.8)873.3 (706.1 to 1080.2)
Omicron JN.13738.8 (2566.9 to 5445.6)4990.5 (3309.3 to 7525.7)4319.5 (3280.7 to 5687.2)1895.8 (1456.8 to 2467.0)2275.2 (1771.0 to 2923.1)2088.6 (1743.9 to 2501.5)
PrimaryGMFR of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control

GMFRs were defined as geometric mean ratios of the results after vaccination to the results before vaccination. GMFRs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis.

Time frame:
From before vaccination on Day 1 up to 1 month after vaccination
Reported as:
Geometric mean · Fold rise
GMFR of SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers From Before Vaccination to 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control
Fold riseSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsSSC- Cohort 3 Combined: All Age GroupsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age Groups
Omicron KP.28.9 (6.3 to 12.5)13.4 (8.1 to 22.1)11.0 (8.1 to 14.8)11.4 (8.5 to 15.4)10.9 (8.1 to 14.7)11.1 (9.0 to 13.7)
Omicron JN.16.6 (4.7 to 9.2)11.7 (6.7 to 20.3)8.8 (6.4 to 12.1)11.2 (8.3 to 15.0)11.4 (8.4 to 15.4)11.3 (9.1 to 13.9)
PrimaryPercentage of Participants With Seroresponse to SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control

Seroresponse was defined as achieving a \>=4-fold rise from baseline (before the study vaccination). If the baseline measurement was below the LLOQ, a postvaccination assay result \>=4 \*LLOQ is considered a seroresponse.

Time frame:
At 1 month after vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse to SARS-CoV-2 Omi KP.2 and Omi JN.1 Variant-Neutralizing Titers at 1 Month After Vaccination in SSC Cohort 3 and Cohorts 1 + 2 Combined as Control
Percentage of participantsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsSSC- Cohort 3 Combined: All Age GroupsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC- Cohort 1 and Cohort 2 Combined: All Age Groups
Omicron KP.277.6 (63.4 to 88.2)76.0 (61.8 to 86.9)76.8 (67.2 to 84.7)71.4 (61.0 to 80.4)63.1 (53.0 to 72.4)67.0 (59.9 to 73.6)
Omicron JN.164.0 (49.2 to 77.1)64.0 (49.2 to 77.1)64.0 (53.8 to 73.4)73.6 (63.3 to 82.3)68.0 (58.0 to 76.8)70.6 (63.7 to 76.9)

Adverse events

Collected over Local reactions and systemic events by systematic assessment: Day 1 to Day 7 after vaccination; Non-systematic assessment: SAEs and all-cause mortality = from Day 1 of vaccination up to 6 months after vaccination and Non-SAEs = from Day 1 of vaccination up to 1 month after vaccination. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SSA - Group 1: 12-17 Years0/30 (0%)1/30 (3.3%)27/30 (90%)
SSA - Group 2: 18-55 Years0/174 (0%)0/174 (0%)154/174 (88.5%)
SSA - Group 3: >55 Years1/208 (0.5%)4/208 (1.9%)134/208 (64.4%)
SSB - Group 1: 12-17 Years0/9 (0%)0/9 (0%)4/9 (44.4%)
SSB - Group 2: 18-55 Years0/253 (0%)2/253 (0.8%)166/253 (65.6%)
SSB - Group 3: >55 Years0/49 (0%)1/49 (2%)25/49 (51%)
SSC - Cohort 2: 12-17 Years0/18 (0%)0/18 (0%)16/18 (88.9%)
SSC - Cohort 1 and Cohort 2 Combined: 18-55 Years0/92 (0%)1/92 (1.1%)77/92 (83.7%)
SSC - Cohort 1 and Cohort 2 Combined: >55 Years1/106 (0.9%)3/106 (2.8%)66/106 (62.3%)
SSC - Cohort 3: 18-55 Years0/51 (0%)0/51 (0%)43/51 (84.3%)
SSC - Cohort 3: >55 Years0/51 (0%)1/51 (2%)35/51 (68.6%)
Most frequent serious events
Showing 10 of 18
Most frequent serious events
EventSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 Years
CellulitisInfections and infestations1/300/1740/2080/90/2530/490/180/920/1060/510/51
Small intestinal obstructionGastrointestinal disorders0/300/1740/2080/90/2531/490/180/920/1060/510/51
Cerebrovascular accidentNervous system disorders0/300/1740/2080/90/2530/490/180/920/1060/511/51
DiverticulitisInfections and infestations0/300/1740/2080/90/2530/490/181/920/1060/510/51
Cervical vertebral fractureInjury, poisoning and procedural complications0/300/1740/2080/90/2530/490/180/921/1060/510/51
Road traffic accidentInjury, poisoning and procedural complications0/300/1740/2080/90/2530/490/180/921/1060/510/51
Subdural haematomaInjury, poisoning and procedural complications0/300/1740/2080/90/2530/490/180/921/1060/510/51
DehydrationMetabolism and nutrition disorders0/300/1740/2080/90/2530/490/180/921/1060/510/51
Respiratory failureRespiratory, thoracic and mediastinal disorders0/300/1740/2080/90/2530/490/180/921/1060/510/51
Viral infectionInfections and infestations0/300/1740/2080/90/2530/490/180/921/1060/510/51
Most frequent other events
Showing 10 of 40
Most frequent other events
EventSSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 Years
Injection site pain (PAIN)General disorders24/30132/174107/2084/9142/25318/4916/1867/9252/10637/5123/51
Headache (HEADACHE)Nervous system disorders11/3076/17454/2081/976/2538/4911/1833/9219/10620/519/51
Fatigue (FATIGUE)General disorders17/3099/17473/2081/987/25312/4910/1844/9231/10630/5117/51
Chills (CHILLS)General disorders6/3016/17419/2081/930/2535/498/1816/929/1064/515/51
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders7/3038/17425/2081/945/2539/496/1816/9211/10617/515/51
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders5/3025/17416/2081/932/2536/492/188/928/1067/512/51
Injection site swelling (SWELLING)General disorders5/3013/17412/2081/930/2535/490/1812/9212/1065/512/51
Pyrexia (FEVER)General disorders5/307/1748/2081/96/2533/492/184/922/1062/512/51
Diarrhoea (DIARRHEA)Gastrointestinal disorders0/3021/17418/2081/942/2534/490/189/928/1066/514/51
Vomiting (VOMITING)Gastrointestinal disorders0/304/1740/2080/912/2531/492/182/921/1061/512/51

Baseline characteristics

Baseline analysis population was evaluated on safety population which included all participants who received the study intervention.

Age, Customized
Age, Customized(Participants)SSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsTotal
Age — 12-17 Years300090018000057
Age — 18-64 Years017463025327092455118723
Age — 65-84 Years0014300220061033259
Age — Greater than or equal to 85 Years002000000002
Sex: Female, Male
Sex: Female, Male(Participants)SSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsTotal
Female19100123513823860583527596
Male1174854115261032481624445
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsTotal
Hispanic or Latino635343136191202969298
Not Hispanic or Latino241381736117301772764442739
Unknown or Not Reported011000001104
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SSA - Group 1: 12-17 YearsSSA - Group 2: 18-55 YearsSSA - Group 3: >55 YearsSSB - Group 1: 12-17 YearsSSB - Group 2: 18-55 YearsSSB - Group 3: >55 YearsSSC - Cohort 2: 12-17 YearsSSC - Cohort 1 and Cohort 2 Combined: 18-55 YearsSSC - Cohort 1 and Cohort 2 Combined: >55 YearsSSC - Cohort 3: 18-55 YearsSSC - Cohort 3: >55 YearsTotal
American Indian or Alaska Native001001011004
Asian111100420664650
Native Hawaiian or Other Pacific Islander002000001003
Black or African American32327787162201667214
White261351642162301560763937746
More than one race0530001462122
Unknown or Not Reported001000010002
08

Study locations

37 sites
  • North Alabama Research Center
    Athens, Alabama 35611, United States
  • Medical Affiliated Research Center
    Huntsville, Alabama 35801, United States
  • Alliance for Multispecialty Research, LLC
    Mobile, Alabama 36608, United States
  • Epic Medical Research - Surprise
    Surprise, Arizona 85378, United States
  • Alliance for Multispecialty Research, LLC
    Tempe, Arizona 85281, United States
  • West Coast Research
    Dublin, California 94568, United States
  • California Research Foundation
    San Diego, California 92123, United States
  • Bayview Research Group, LLC
    Valley Village, California 91607, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Clinical Research Consulting
    Milford, Connecticut 06460, United States
  • Indago Research & Health Center, Inc
    Hialeah, Florida 33012, United States
  • Clinical Neuroscience Solutions, Inc. dba CNS Healthcare
    Jacksonville, Florida 32256, United States
  • Care Research - West Flagler Street
    Miami, Florida 33130, United States
  • Acevedo Clinical Research Associates
    Miami, Florida 33142, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Clinical Research Atlanta
    Stockbridge, Georgia 30281, United States
  • East-West Medical Research Institute
    Honolulu, Hawaii 96814, United States
  • Kentucky Pediatric/ Adult Research
    Bardstown, Kentucky 40004, United States
  • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
    Springfield, Missouri 65802, United States
  • Bio-Kinetic Clinical Applications LLC DBA QPS_MO (Patient Screening Only)
    Springfield, Missouri 65807, United States
  • M3 Wake Research, Inc.
    Raleigh, North Carolina 27612, United States
  • Centricity Research Columbus Ohio Multispecialty
    Columbus, Ohio 43213, United States
  • Dayton Clinical Research
    Dayton, Ohio 45409, United States
  • Senders Pediatrics
    South Euclid, Ohio 44121, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37909, United States
  • Alliance for Multispecialty Research, LLC
    Knoxville, Tennessee 37920, United States
  • Clinical Neuroscience Solutions Inc.
    Memphis, Tennessee 38119, United States
  • Zenos Clinical Research
    Dallas, Texas 75230, United States
  • Epic Medical Research - DeSoto
    DeSoto, Texas 75115, United States
  • DM Clinical Research - Bellaire
    Houston, Texas 77081, United States
  • SMS Clinical Research
    Mesquite, Texas 75149, United States
  • IMA Clinical Research San Antonio
    San Antonio, Texas 78229, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Alliance for Multispecialty Research, LLC
    Layton, Utah 84041, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic
    Salt Lake City, Utah 84109, United States
  • J. Lewis Research, Inc. / Foothill Family Clinic South
    Salt Lake City, Utah 84121, United States
  • Alliance for Multispecialty Research, LLC
    Norfolk, Virginia 23502, United States
09

References and documents

Publications

  • Diya O, Gayed J, Lowry FS, Ma H, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Cutler M, Belanger T, Cooper D, Xu X, Mogg R, Tureci O, Sahin U, Swanson KA, Modjarrad K, Anderson AS, Gurtman A, Kitchin N. Safety and Immunogenicity of Monovalent Omicron KP.2-Adapted BNT162b2 COVID-19 Vaccine in Adults: Single-Arm Substudy from a Phase 2/3 Trial. Infect Dis Ther. 2025 Aug;14(8):1973-1987. doi: 10.1007/s40121-025-01185-4. Epub 2025 Jul 1. PubMed 40591130 ↗
  • Diya O, Gayed J, Lowry FS, Ma H, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Cutler M, Belanger T, Cooper D, Xu X, Koury K, Tureci O, Sahin U, Swanson KA, Modjarrad K, Anderson AS, Gurtman A, Kitchin N. A phase 2/3 trial to investigate the safety and immunogenicity of monovalent Omicron JN.1-adapted BNT162b2 COVID-19 vaccine in adults >/=18 years old. Vaccine. 2025 Apr 11;52:126869. doi: 10.1016/j.vaccine.2025.126869. Epub 2025 Feb 24. PubMed 39999538 ↗
  • Gayed J, Bangad V, Xu X, Mensa F, Cutler M, Tureci O, Sahin U, Modjarrad K, Swanson KA, Anderson AS, Gurtman A, Kitchin N; C4591054 Study Group. Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine against XBB.1.5, BA.2.86, and JN.1 Sublineages: A Phase 2/3 Trial. Vaccines (Basel). 2024 Jul 2;12(7):734. doi: 10.3390/vaccines12070734. PubMed 39066372 ↗
  • Gayed J, Diya O, Lowry FS, Xu X, Bangad V, Mensa F, Zou J, Xie X, Hu Y, Lu C, Cutler M, Belanger T, Cooper D, Koury K, Anderson AS, Tureci O, Sahin U, Swanson KA, Modjarrad K, Gurtman A, Kitchin N; C4591054 Study Group. Safety and Immunogenicity of the Monovalent Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine in Individuals >/=12 Years Old: A Phase 2/3 Trial. Vaccines (Basel). 2024 Jan 24;12(2):118. doi: 10.3390/vaccines12020118. PubMed 38400102 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Mar 2025, 19 months.

Results were first posted in Apr 2026, 1 year 1 month after primary completion.

Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 18. This study's 19 months is above that.

Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 10, 2023
First posted
Aug 18, 2023
StartActual
Aug 10, 2023
Primary completionActual
Mar 13, 2025
CompletionActual
Mar 13, 2025
Results first posted
Apr 28, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05997290
Lead sponsor
BioNTech SE
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Aug 18, 2023
Start date
Aug 10, 2023
Primary completion
Mar 13, 2025
Completion
Mar 13, 2025
Results posted
Apr 28, 2026
Last update
Apr 28, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: BNT162 Vaccine

Start the discussion